PURPOSE To provide evidence-based recommendations for practicing physicians and
other healthcare providers on the management of salivary gland malignancy. METHODS …

Salivary gland cancers (SGCs), categorized as head and neck cancers (HNCs), constitute
about 6% of head and neck cancer diagnoses based on estimate by American Head and …

Salivary duct carcinoma (SDC) is a rare, aggressive salivary malignancy that is often
diagnosed at an advanced stage. Previously, little was known about outcomes of this …

Salivary duct carcinoma (SDC) is a subtype of salivary gland cancer with a dismal prognosis
and a need for better prognostication and novel treatments. The aim of this national cohort …

Background: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-
targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent …

Salivary gland malignancies are rare neoplasms that have a broad histological spectrum
and a variety of biologic behaviors. Salivary gland malignancies are known as chemo …

Aim Salivary duct carcinoma (SDC), an aggressive subtype of salivary gland cancer, is
androgen receptor (AR)–positive in 67–96% of cases. In patients with locally recurrent and …

Objectives: There is a lack of effective therapy for recurrent or metastatic salivary gland
carcinoma. Androgen deprivation therapy has demonstrated efficacy in cases of salivary …

Salivary gland cancer (SGC) is a rare malignancy consisting of 22 subtypes with different
genetic, histological and clinical characteristics. This rarity and heterogeneity makes …

Introduction To investigate whether the positive lymph node number (PLNN) and positive
lymph node ratio (PLNR) could predict the prognosis of patients with major salivary gland …